Combined-Modality Therapy for Rectal Cancer Using Irinotecan

OncologyONCOLOGY Vol 16 No 5
Volume 16
Issue 5

Preoperative or postoperative pelvic radiation plus concurrent fluorouracil-based chemotherapy is standard adjuvant treatment for patients with T3 and/or N1/2 rectal cancer. Newer chemotherapeutic regimens have been developed for the treatment of patients with metastatic disease.

ABSTRACT: Preoperative or postoperative pelvic radiation plus concurrent fluorouracil-based chemotherapy is standard adjuvant treatment for patients with T3 and/or N1/2 rectal cancer. Newer chemotherapeutic regimens have been developed for the treatment of patients with metastatic disease. Irinotecan (CPT-11, Camptosar)-based regimens have improved survival in patients with metastatic disease and are being actively investigated in combination with pelvic radiation therapy for patients with rectal cancer. [ONCOLOGY 16(Suppl5):35-38, 2002]

The standard adjuvant treatment for patients with T3and/or N1/2 rectal cancer is pelvic radiation plus concurrent fluorouracil(5-FU)-based chemotherapy. Several newer chemotherapeutic regimens have beendeveloped for the treatment of patients with metastatic disease and are nowbeing combined with pelvic radiation therapy. This review will focus on theresults of irinotecan (CPT-11, Camptosar)-based regimens in combination withradiation therapy in patients with rectal cancer.

Adjuvant Therapy With 5-FU-Based Regimens: Postoperative Therapy

Published results of randomized trials from the Gastrointestinal Tumor StudyGroup (GITSG)[1,2] and the Mayo/NCCTG (North Central Cancer Treatment Group,trial 79-47-51)[3] revealed significant improvements in local control and/orsurvival with postoperative radiation plus bolus 5-FU with or without semustine(methyl-CCNU) in patients with rectal cancer. Based on these findings, theNational Cancer Institute Consensus Conference concluded in 1990 thatcombined-modality therapy with 5-FU-based regimens was the standardpostoperative adjuvant treatment for patients with T3 and/or N1/2 rectalcancer.[4] While radiation therapy decreases local recurrence rates by half, theaddition of 5-FU-based chemotherapy further decreases local recurrence ratesto approximately 10% to 12%, and is responsible for increasing overall 5-year survival rates by approximately 10% to 15% above those achieved withsurgery alone. Data from the National Surgical Adjuvant Breast and Bowel Project(NSABP) R-02 randomized trial revealed that, although postoperative 5-FU-basedchemotherapy alone decreased the local recurrence rate to 13%, the combinationof chemotherapy plus radiation significantly decreased the local recurrence rateto 8%.[5]

Based on the positive results reported in the Mayo/NCCTG 86-47-51 trial thatused continuous infusion 5-FU, the postoperative Intergroup trial INT 0144 wasdesigned. The primary end point of this trial was to determine whether there wasa benefit of continuous infusion 5-FU throughout the entire chemotherapy course(six cycles) as compared with continuous infusion only during thecombined-modality segment (two cycles) and bolus 5-FU during the remaining fourcycles. The control arm was bolus 5-FU/leucovorin/levamisole (Ergamisol). Thetrial closed to accrual in 2000 and the results are pending.

Until the results of INT 0144 are available, the choice of a postoperativeadjuvant regimen in the nonprotocol setting remains controversial. If 5-FU aloneis used, then it is probably best administered by continuous infusion.Otherwise, published data on 5-FU-based regimens indicate that they areprobably equally effective; the choice of a regimen should be based on factorssuch as acute toxicity profiles and patient compliance.

Adjuvant Therapy With 5-FU-Based Regimens: Preoperative Therapy

Given the advantage of chemotherapy in the postoperative setting, severalphase I/II preoperative combined-modality treatment programs have beendeveloped. Most have used 5-FU-based chemotherapy. Retrospective data suggestthat preoperative combined-modality therapy increases pathologic down-stagingcompared with preoperative radiation alone[6] and is associated with a lowerincidence of acute toxicity compared with postoperative combined-modalitytherapy.[7]

Preoperative therapy may also increase sphincter preservation. Seven seriesexamining this issue have been reported. The studies were carried out inpatients with clinically resectable rectal cancer whose surgeons had determinedprospectively (based on a clinical office exam before beginning preoperativetherapy) that they required abdominoperineal resection. All of the studiedregimens used conventional radiation doses and techniques—three with radiationtherapy alone[8-10] and four as combined-modality therapy.[11-14]

Results showed that the incidence of sphincter preservation afterpreoperative therapy was only 23% in the NSABP R-03 series[11] and 44% in theLyon series[10]; however, approximately 70% of patients in the remaining fiveseries had sphincter preservation. In the four series reporting functionaloutcome, the majority of patients (approximately 75%) had good to excellentsphincter outcome.

Some investigators have concluded that it is not necessary to addchemotherapy to preoperative radiation therapy. For example, in the SwedishRectal Cancer Trial, patients received an intensive short course of preoperativeradiation (5 Gy × 5) vs surgery alone.[15] Patients randomized to thepreoperative radiation group had a significant decrease in local recurrence rate(12% vs 27%, P < .001) and an improved 5-year survival rate (58% vs 48%, P =.004).

These impressive results should be analyzed in the context of other publishedliterature: First, given that the other 11 randomized trials of preoperativeradiation therapy did not report a survival benefit, these data clearly need tobe confirmed by additional studies.[16] Second, even if future trials confirm asurvival benefit, there are other equally important end points in rectal cancerthat need to be addressed. These include morbidity, mortality, and sphincterpreservation and function, all of which are adversely affected by intensiveshort-course preoperative radiation.[17,18] Lastly, the Dutch CKVO 95-04 trial,in which a total mesorectal excision was mandated and patients underwent thesame intensive short-course preoperative randomization to 5 Gy × 5 vs surgeryalone, reported a significant decrease in local recurrence rate withpreoperative radiation (2% vs 8%); however, the survival advantage reported inthe Swedish Rectal Cancer Trial was not demonstrated.[19]

To address whether chemotherapy (bolus 5-FU/leucovorin) is necessary eitherconcurrently with preoperative radiation and/or postoperatively, the EuropeanOrganization for Research and Treatment of Cancer (EORTC) is conducting thedefinitive randomized trial (EORTC 22921). The results are pending at this time.

When the goal of preoperative therapy is sphincter preservation, conventionaldoses and techniques of radiation are recommended. These include multiple-fieldtechniques to a total dose of 4,500 to 5,040 cGy at 180 cGy/fraction. Surgeryshould be performed a minimum of 4 weeks following completion of radiation.Unlike the intensive short course of radiation, this conventional design allowsfor recovery from acute side effects of radiation and enhances tumordown-staging. Data from the Lyon trial of preoperative radiation suggest that aninterval greater than 2 weeks following completion of radiation increases thechance of downstaging.[10]

Clearly, randomized trials are needed to confirm the suggestion of decreasedacute toxicity and enhanced sphincter preservation with preoperative therapy.Three randomized trials of preoperative vs postoperative combined modalitytherapy for clinically resectable T3 rectal cancer have been developed. Two arefrom the United States (INT 0147, NSABP R-03) and one is from Germany (CAO/ARO/AIO94). The three studies used conventional doses and techniques of radiationtherapy and concurrent 5-FU-based chemotherapy. A preoperative clinicalassessment to determine the type of operation indicated was also required.

Unfortunately, low accrual has resulted in early closure of both the INT 0147and NSABP R-03 trials. The German CAO/ARO/AIO 94 trial completed accrual of morethan 800 patients. It is the only trial that can adequately address the issuesof toxicity, efficacy, and sphincter preservation. A preliminary analysis of theNSABP R-03 trial, albeit underpowered with only 300 of the planned 900 patientsaccrued, revealed that patients who received preoperative therapy had a higherchance of having sphincter-sparing surgery and achieving disease-free status(44% vs 34%); however, this group also had an unexplained increase in grade 4 +toxicity (34% vs 23%).[20]

Preoperative Therapy Using Newer Chemotherapeutic Regimens

Several phase I/II trials of preoperative combined-modality therapy usingnewer chemotherapeutic agents such as raltitrexed (Tomudex),[21] UFT (uracil andtegafur)/leucovorin,[22] irinotecan,[23-27] oxaliplatin,[28] and capecitabine(Xeloda)[29] for patients with both resectable and unresectable disease areunder way. Additional trials are also examining targeted therapies such as C225and SU5416 (Iressa).

The significant survival advantage of irinotecan/5-FU/leucovorin vs5-FU/leucovorin or irinotecan alone in patients with metastatic colorectalcancer has generated considerable interest in integrating irinotecan intopreoperative combined-modality therapy regimens for rectal cancer.[30] Fivephase I or II trials are using combined irinotecan with radiation therapy. Twoof the trials assessed irinotecan as monotherapy[23,24] and three assessedirinotecan combined with 5-FU.[25-27]

Irinotecan Alone in Combined-Modality Therapy

Minsky et al[23] reported results of a phase I trial of escalating doses ofweekly irinotecan (8 to 13 mg/m² daily) administered weeks 1, 2, 4, and 5, plusconcurrent radiation at 50.4 Gy in 28 patients with T3/4 rectal cancer. Among 16patients treated at the recommended dose of 10 mg/m², the pathologic completeresponse rate was 5% and the grade 3 + acute toxicity rate was 29%. Becausethese results were inferior to those achieved previously with 5-FU/leucovorin-basedregimens tested at Memorial Sloan-Kettering Cancer Center,[14] this single-agentirinotecan regimen was not tested in the phase II setting.

Another trial of irinotecan alone with preoperative radiation was reported byVolter and colleagues from Lausanne.[24] A total of 20 patients with T3/4 rectalcancer were entered in this phase I trial. The irinotecan dose was escalatedfrom 30 to 105 mg/m² weekly × 3; hyperfractionated radiation (1.6 Gy bid to atotal dose of 41.6 Gy) began on week 2. There was a high incidence ofanastomotic leak and/or abscess (30%), which may have been partly related to thehyperfractionated radiation. The recommended dose level of irinotecan was 90mg/m².

Irinotecan Combination Regimens in Combined-Modality Therapy

In the remaining three trials of irinotecan in combined-modality therapy,5-FU was added to the preoperative radiation/irinotecan combination. Klautke andassociates from the University of Rostock performed a phase II trial in 26patients with various stages of rectal cancer.[26] Doses were fixed: irinotecan(40 mg/m² weekly), 5-FU (250 mg/m² by continuous infusion), and radiationtherapy (50.4 Gy). Grade 3 + toxicities were hematologic (15%) and diarrhea(35%). The 15 patients who underwent surgery had an impressive complete responserate (26% pathologic and 26% clinical).

Even higher complete response rates were reported in a phase II trial fromMetha and coworkers from Stanford University Medical Center.[25] A total of 22patients with T3 disease received irinotecan (50 mg/m² weekly × 4), 5-FU (200mg/m² by continuous infusion), and radiation at 50.4 Gy. Grade 3 + acutetoxicities were diarrhea (20%) and mucositis (15%). Among 18 patients whounderwent surgery, the complete response rates were 67% pathologic and 17%clinical.

The largest study was reported by Mitchell and colleagues from ThomasJefferson University.[27] In this phase I trial, 46 patients with T3/4 rectalcancer received irinotecan (30 to 60 mg/m² weekly × 4), 5-FU (225 to 300mg/m²by continuous infusion), and radiation therapy (45 to 54 Gy). This trial hadboth escalation and attenuation of the irinotecan, 5-FU, and radiation doses.Overall, there was a 24% pathologic complete response rate and a 15% clinicalcomplete response rate. Interestingly, patients whose tumors had evidence ofmicrosatellite instability had a higher complete response rate compared withthose without microsatellite instability. The recommended dose levels wereirinotecan at 50 mg/m² weekly × 4, 5-FU at 225 mg/m² daily × 5, and radiationtherapy at 54 Gy. This regimen is being compared with a regimen of preoperativecontinuous infusion 5-FU plus radiation bid in the randomized phase II RadiationTherapy Oncology Group (RTOG) protocol R-0012.


In summary, the ideal irinotecan-based preoperative combined-modality regimenhas not been determined. Results from phase I/II trials suggest thatpreoperative irinotecan plus radiation therapy is most effective when used incombination with 5-FU. This is consistent with data from the randomized trialthat revealed a significant survival benefit in patients with advancedcolorectal cancer.[30] While preliminary data reveal encouragingly high completeresponse rates, it should be emphasized that these rates need to be comparedwith those achievable with 5-FU-based therapy in randomized trials.

5-FU-based combined-modality therapy remains the standard of care forpatients with T3/4 rectal cancer. In addition to irinotecan, a number of newerchemotherapeutic agents are available and should be examined in preoperative andpostoperative combined-modality therapy regimens in patients with rectal cancer.


1. Gastrointestinal Tumor Study Group: Prolongation of the disease-freeinterval in surgically treated rectal carcinoma. N Engl J Med 312:1465-1472,1985.

2. Gastrointestinal Tumor Study Group: Adjuvant therapy of colon cancer:Results of a prospectively randomized trial. N Engl J Med 310:737-743, 1984.

3. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvanttherapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991.

4. National Institutes of Health Consensus Conference: Adjuvant therapy forpatients with colon and rectal cancer. J Am Med Assoc 264:1444-1450, 1990.

5. Wolmark N, Weiand HS, Hyams DM, et al: Randomized trial of postoperativeadjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum:National Surgical Adjuvant Breast and Bowel Project protocol R-02. J Natl CancerInst 92:388-396, 2000.

6. Minsky BD: Primary treatment of rectal cancer: Present and future. CritRev Oncol Hematol 32:19-30, 1999.

7. Minsky BD, Cohen AM, Enker WE, et al: Combined modality therapy of rectalcancer: Decreased acute toxicity with the pre-operative approach. J Clin Oncol10:1218-1224, 1992.

8. Wagman R, Minsky BD, Cohen AM, et al: Sphincter preservation withpreoperative radiation therapy and coloanal anastomosis: Long term follow-up.Int J Radiat Oncol Biol Phys 42:51-57, 1998.

9. Rouanet P, Fabre JM, Dubois JB, et al: Conservative surgery for low rectalcarcinoma after high-dose radiation. Functional and oncologic results. Ann Surg221:67-73, 1995.

10. Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the intervalbetween preoperative radiation therapy and surgery on downstaging and on therate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomizedtrial. J Clin Oncol 17:2396-2402, 1999.

11. Hyams DM, Mamounas EP, Petrelli N, et al: A clinical trial to evaluatethe worth of preoperative multimodality therapy in patients with operablecarcinoma of the rectum. A progress report of the National Surgical AdjuvantBreast and Bowel Project protocol R0-3. Dis Colon Rectum 40:131-139, 1997.

12. Valentini V, Coco C, Cellini N, et al: Preoperative chemoradiation forextraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincterpreservation. Int J Radiat Oncol Biol Phys 40:1067-1075, 1998.

13. Maghfoor I, Wilkes J, Kuvshinoff B, et al: Neoadjuvant chemoradiotherapywith sphincter-sparing surgery for low lying rectal cancer. Proc Am Soc ClinOncol 16:274a, 1997.

14. Grann A, Feng C, Wong D, et al: Preoperative combined modality therapyfor clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol BiolPhys 49:987-995, 2001.

15. Swedish Rectal Cancer Trial: Improved survival with preoperativeradiotherapy in resectable rectal cancer. N Engl J Med 336:980-987, 1997.

16. Skibber JM, Hoff PM, Minsky BD: Cancer of the rectum, in DeVita VT,Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6thed, pp 1271-1318. Philadelphia, Lippincott, Williams, and Wilkins, 2001.

17. Holm T, Singnomklao T, Rutqvist LE, et al: Adjuvant preoperativeradiotherapy in patients with rectal carcinoma. Adverse effects during long termfollow-up of two randomized trials. Cancer 78:968-976, 1996.

18. Holm T, Rutqvist LE, Johansson H, et al: Postoperative mortality inrectal cancer treated with or without preoperative radiotherapy: Causes and riskfactors. Br J Surg 83:964-968, 1996.

19. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al: Preoperative radiotherapyin combination with total mesorectal excision improves local control inresectable rectal cancer. N Engl J Med 345:638-646, 2001.

20. Roh MS, Petrelli N, Weiand H, et al: Phase III randomized trial ofpreoperative versus postoperative multimodality therapy in patients withcarcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 20:123a, 2001.

21. Valentini V, Morganti AG, Luzi S, et al: Chemoradiation with raltitrexed(Tomudex) and oxaliplatin in preoperative treatment of stage II/III resectablerectal cancer: A dose finding study. Proc Am Soc Clin Oncol 20:131a, 2001.

22. Fernandez-Martos C, Aparicio J, Bosch C, et al: Preoperative therapy (PT)with oral uracil and tegafur (UFT) and concomitant irradiation (RT) in operablerectal cancer (RC). Preliminary results of a multicenter phase II study. Proc AmSoc Clin Oncol 20:148a, 2001.

23. Minsky BD, O’Reilly E, Wong D, et al: Daily low-dose irinotecan(CPT-11) plus pelvic irradiation as preoperative treatment of locally advancedrectal cancer. Proc Am Soc Clin Oncol 18:266a, 1999.

24. Volter V, Stupp R, Matter M, et al: Preoperative hyperfractionatedaccelerated radiotherapy (HART) and concomitant CPT-11 in rectal carcinoma. ProcAm Soc Clin Oncol 20:126b, 2001.

25. Mehta VK, Fisher G, Cho C, et al: Phase II trial of preoperativeradiotherapy, protracted venous infusion, 5-fluorouracil, and weekly CPT-11followed by surgery for ultrasound staged T3/T4 rectal cancer. Proc Am Soc ClinOncol 20:148a, 2001.

26. Klautke G, Kirchner R, Hopt U, et al: Continuous infusion of 5-FU andweekly irinotecan with concurrent radiotherapy as neoadjuvant treatment forlocally advanced or recurrent rectal cancer. Proc Am Soc Clin Oncol 20:140a,2001.

27. Mitchell EP, Anne P, Fry R, et al: Combined modality therapy of locallyadvanced or recurrent adenocarcinoma of the rectum: Report of a phase I trial ofchemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT). Proc AmSoc Clin Oncol 20:131a, 2001.

28. Sebag-Montefiore D, Tim M, Stephen F, et al: A phase I dose escalationstudy of oxaliplatin when given in combination with 5-fluorouracil (5-FU), lowdose folinic acid (LDFA) and synchronous pre-operative radiotherapy (RT) inlocally advanced rectal cancer. Proc Am Soc Clin Oncol 20:147a, 2001.

29. Dunst J, Reese T, Frings S: Phase I study of capecitabine combined withsimultaneous radiotherapy in rectal cancer. Proc Am Soc Clin Oncol 20:149a,2001.

30. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil andleucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.